Skip to Content

Real-World Studies Highlight NSCLC Data Gaps and Survival Differences from Randomized Controlled Trials

In this MEDtalk, Birgitte Bjørnhart of the Department of Oncology at Odense University Hospital presents the outcomes of two national studies involving the treatment of non-small cell lung cancer (NSCLC) patients with immune-checkpoint inhibitors. During her presentation, she examines the differences between real-world studies and randomized controlled trials.

Birgitte Bjørnhart

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top